Breaking the myths: Consensus statements from local rheumatologists recommend covid-19 vaccination in patients with autoimmune rheumatic diseases
The Hong Kong Society of Rheumatology (HKSR) published a set of consensus statements for Coronavirus Disease 2019 (COVID-19) vaccination in adult patients with autoimmune rheumatic diseases (ARDs). This statement serves as a guide to local rheumatologists and other specialists, nurses, healthcare professionals and the public regarding the use of COVID-19 vaccines in patients with ARDs.
ARD is a group of chronic medical illness characterized by systemic inflammation, in which a dysregulated immune system causes damage or dysfunction to connective tissues and leads to various treatment-related complications and comorbidities.1,2 In the current COVID-19 pandemic, patients with pre-existing chronic health conditions are more prone to serious illness and mortality from the infection, arousing concerns among patients with ARDs regarding their suitability for the COVID-19 vaccination.1,3
The concerns about the COVID-19 vaccines from the patient community were observed in a web-based questionnaire study, in which 32.2% of 1,266 patients with systemic rheumatic diseases reported uncertainty about the COVID-19 vaccination, and 13.6% of the population were unwilling to get vaccinated.4 The main concerns from the patients were the scarcity of experience and background information regarding the new COVID-19 vaccines, the use of a new vaccination technology, possible induction of a disease flare, and the risk of developing local reactions or side effects.4 However, the willingness to get vaccinated increased when the vaccination was recommended by specialists, with a reported uncertainty declined to 28.4% and unwillingness to 8.8%.4 This emphasizes the timely and critical involvement of rheumatologists in vaccination uptake, highlighting the importance of professional advice and accurate information education when encouraging COVID-19 vaccination.1,4
Considering the need of a guide to address patients’ concerns, the HKSR developed a comprehensive set of consensus statements for the use of COVID-19 vaccines among local patients with ARDs, clarifying the relationship between the pandemic, vaccination, ARDs, and immunosuppressive treatments.1
Clinical questions regarding the COVID-19 vaccination in adult patients with ARDs were discussed by 27 core members of the HKSR, including council members and rheumatologist-in-charge of most public hospitals.1 The discussion was summarized into six clinical questions afterward, using the PICO (problem/population, intervention, comparison and outcomes) approach.1 A systemic literature search (SLR) in PubMed was subsequently conducted to identify the evidence for the consensus statements, covering only clinical trials, cohort studies and case series published in English from December 2019 to March 28, 2021.1
Prior to the Delphi exercise, the strength of evidence (SoR) and quality of evidence (QoE) were evaluated for each of the eight finalized statements based on the Grades of Recommendations Assessment, Development and Evaluation (GRADE) system (Table 1).1 Also provided with the results of the SLR and explanatory notes, full members of the HKSR were invited to anonymously indicate the level of agreement by arbitrary scores, provide feedback, indicate reasons for disagreement and suggest modifications for the statements.1 Statements were subjected to amendments and subsequent rounds of voting until at least 80% of Delphi participants agreed for all statements.1
Results and discussion
A total of 55 full members of HKSR participated in the Delphi exercise, representing more than 60% of the local practicing rheumatologists with the majority working in public hospitals.1 With consideration of the existing evidence and local perspectives such as the availability of specific vaccines and the outbreak situation, consensus of the statements was reached after two rounds of voting (Table 2).
Dr. So, Ho and Dr. Yip, Man-Lung Ronald, authors of the consensus statements as well as core members of the HKSR, noted that the consensus statements would address the concerns regarding the COVID-19 vaccines and encourage vaccination among patients with ARDs. Although there is growing evidence suggesting that immunosuppressive treatments would affect the antibody response to the COVID-19 vaccines, Dr. So noted that an antibody response may not reflect the efficacy of vaccines. Clinically, there is no evidence of COVID-19 vaccination increasing the ARD activity or the risk of acquiring vaccine-related side effects, such as facial paralysis, in adult patients with ARDs. “As the COVID-19 vaccines available in Hong Kong are not live-attenuated vaccines, the risk of developing COVID-19 infection through vaccination is not possible in patients with ARDs,” reiterated Dr. So when considering the safety of COVID-19 vaccination in patients with ARDs.
When mentioning the balance between the treatment for ARDs and COVID-19, Dr. Yip emphasized the importance of early treatment and the treat-to-target approach in ARD management, highlighting that adjustments in the ARDs treatment regimen in view of the COVID-19 pandemic, as well as the COVID-19 vaccination, are not recommended. “There is growing evidence showing that with earlier treatment, the disease control will be easier, leading to a better prognosis, higher remission rate, and lower occurrence of comorbidities and physical disabilities,” stated Dr. Yip. Dr. So also supported this opinion with guidelines from the United States, the European Union and Asia, stating that treatments for ARDs should not be discontinued in the pandemic as active rheumatic diseases also increase the risk of COVID-19 infection and severity. Importantly, ARD treatments involving immunosuppression should not be compromised for the vaccination. That said, postponement of rituximab infusion or COVID-19 vaccination may be considered as B-cell depleting therapy may reduce the protective immunity against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) following COVID-19 vaccination.5 Patients with uncontrolled disease activity are also recommended to hold COVID-19 vaccination until their diseases are stable, Dr. Yip noted.
Both Dr. So and Dr. Yip expressed their wishes for the consensus statements to improve patients’ confidence towards COVID-19 vaccines. By participating in interviews, translating the statements into lay terms in Chinese language, and proactively addressing the concerns of the vaccines through patient support groups, they hoped that the local patient community will understand that the benefits of COVID-19 vaccination can actually outweigh the risks. Dr. So concluded, although more data regarding the efficacy of the vaccines is needed, it should not affect the decision on COVID-19 vaccination and the treatment for ARDs. Dr. Yip agreed, summarizing that “The discontinuation of routine treatment is not required to accommodate COVID-19 vaccination in most patients with ARDs. Also, as vaccination is generally beneficial to our patients during the current pandemic situation, we encourage patients with stable, controlled ARDs to receive COVID-19 vaccination.”
Early molnupiravir and nirmatrelvir-ritonavir show substantial clinical benefits in local hospitalized COVID-19 patients
In a local retrospective cohort study analyzing data during Hong Kong’s omicron BA.2 wave, molnupiravir and nirmatrelvir-ritonavir were found to be effective in reducing the risks of all-cause mortality and disease progression, as well as the need for oxygen therapy among hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and without supplemental oxygen requirement.1 The study revealed the substantial clinical benefits of oral antivirals, supporting their early use among Coronavirus disease 2019 (COVID-19) patients in Hong Kong.1
Early molnupiravir and nirmatrelvir-ritonavir show substantial clinical benefits in local hospitalized COVID-19 patients
In a local retrospective cohort study analyzing data during Hong Kong’s omicron BA.2 wave, molnupiravir and nirmatrelvir-ritonavir were found to be effective in reducing the risks of all-cause mortality and disease progression, as well as the need for oxygen therapy among hospitalized patients due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and without supplemental oxygen requirement.1 The study revealed the substantial clinical benefits of oral antivirals, serving as evidence to support their early use among Coronavirus disease 2019 (COVID-19) patients in Hong Kong.1
Safeguard children’s health from Omicron-associated complications with BNT162b2
The fifth wave of Coronavirus disease 2019 (COVID-19) has caused more than a million people being infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron BA.2, predominant) and over 9,000 COVID-19-associated deaths in Hong Kong.1 Children, a subgroup of the population who had experienced more favorable outcomes vs. the older adults during the first 4 waves of the pandemic, were reported to have disproportionately higher hospitalization rates under the Omicron era.2 Some studies revealed that seizure and laryngotracheobronchitis, or croup, were common severe complications which led to pediatric hospitalization.2 The findings highlighted the importance of COVID-19 vaccination among children, but those aged <5 years were still not eligible for this mitigation measure. In an interview with Omnihealth Practice, Dr. Leung, Sze-Yin Agnes presented the latest safety and efficacy data of BNT162b2 among children aged ≥6 months and encouraged parents to arrange COVID-19 vaccination for their children to reduce the negative impact of this pandemic in young children.
Addition of molnupiravir in the evolving SARS-CoV-2 treatment landscape
At a symposium organized by the Hong Kong Society for Infectious Diseases, Dr. Marissa Grifasi Williams kicked off the symposium by sharing how the evolution of virus has changed the management of SARS-CoV-2, highlighting the current guidelines to recommend molnupiravir as an oral therapy for the coronavirus disease 2019 (COVID-19). She further discussed the MOVe-OUT trial, which demonstrated that molnupiravir reduced the risk of hospitalization or death in at-risk and unvaccinated COVID-19 adults. Concluding her presentation, Dr. Williams featured the additional data of molnupiravir from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2022, validating that molnupiravir was effective in clearing the virus as early as 3 days, as well as improving symptoms. Then, Dr. Yap, Yat-Hin Desmond shared his experience in managing COVID-19 patients with renal failure in Hong Kong.
Multi-peptide CoVac-1 vaccine induces T-cell immunity in immunoglobulin-deficient cancer patients
In the American Association for Cancer Research (AACR) annual meeting 2022, Dr. Claudia Tandler from the University of Tübingen, Germany, discussed the safety and immunogenicity of a novel multi-peptide vaccine, CoVac-1, for the induction of a (SARS-CoV-2) T-cell immunity in cancer patients with dis
BNT162b2 boosters and beyond: Strategies to overcome waning immune responses against omicron variant
During the fifth wave of Coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [B.1.1.529 (Omicron), predominant] infected over a million people and claimed more than 9,000 lives in Hong Kong.1 Elderly people aged ≥60 years were the most vulnerable population and accounted for ≥95% of the total death cases.1 Among the deceased, most were unvaccinated (>70%), or had received only 1 dose of COVID-19 vaccine, and/or were with known chronic diseases.1 Even for people who have received 2 doses of vaccines, increasing evidence showed that protection against severe COVID-19 would be reduced due to the waning immune responses against the Omicron variant.2 As such, in an interview with Omnihealth Practice, Professor HUNG, Fan-Ngai Ivan, addressed the rising concern about Omicron and presented the latest data showing that BNT162b2 boosters are still highly effective against the new threat. He also provided some updates on the development of new Omicron-adapted vaccines for conferring better protection to people.
Emerging from covid-19 predicament: An update on its management and vaccination
The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has afflicted more than 200 million people, with a death toll of more than 4 million people worldwide.1 As of September 29, 2021, Hong Kong has recorded 12,210 COVID-19 cases with 213 deaths.2 Although the situation in Hong Kong has been stabilized since the end of the fourth wave of epidemic in May 2021, the emergence of variants, especially the Delta variants, could be another threat to our society.3,4 In a lecture held by the Macau Association of Health Service Executives (MAHSE), Professor Hung, Fan-Ngai Ivan addressed the concerns over the emergence of the Delta variant and provided an update on the COVID-19 management and vaccination.
Latest updates: Six-month safety and efficacy of BNT162b2 mRNA COVID-19 vaccine
In brief With up to 6 months of follow-up in an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy study, the 6-month safety and efficacy data of BNT162b2 mRNA COVID-19 have been updated and summarized in this report.1 Background The current outbreak of the novel coron
The myths and facts of COVID-19 vaccination and boosters: Current strategies and foresight
Since launching the COVID-19 Vaccination Program in Hong Kong, over 50% of the total population has received the 1st vaccine dose.1 Currently, some studies point out that the immunogenicity varies greatly across the COVID-19 vaccines locally available, sparking controversy on the pro
High prevalence of thrombotic complications found in ICU-admitted COVID-19 patients, systematic screening warranted
Ever since the report of the very first case of coronavirus disease 2019 (COVID-19) in Wuhan back in December 2019, increasing evidence indicates that COVID-19 is associated with a high thrombotic risk.1,2 While the underlying mechanism of thrombus formation among COVID-19 patients had been well-inv